Skip to main content

Table 4 Pharmacokinetics of artemether–lumefantrine during pregnancy

From: A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy

Publication Description Median (range) Day 7 lumefantrine concentration Median (range) lumefantrine Cmax Lumefantrine exposure Artemether exposure (AUC0→8h)
McGready et al., 2006[21] Pharmacokinetic study of AL in pregnancy using venous plasma samples (n = 13). Results compared with a previous report in non-pregnant adults (n = 17) 384 ng/ml (62–835)* 7340 ng/ml (1,590–15,670)* Pregnant: 237 μg/ml.h (90% predicted range 75–576), Non-pregnant: 251 μg/ml.h (90% predicted range 79–616) Pregnant, median (90% range): 66.4 ng/ml.h (10.5–264.8), Non-pregnant, mean (SD): 211 ng/ml.h (109)
Tarning et al., 2009[37] Pharmacokinetic study of AL in pregnancy using capillary plasma samples (n = 103) Capillary plasma: 391 ng/ml (126–1,600), venous plasma (approx): 310 ng/ml (94–1,364)   AUC0→∞, median (range): 472 μg/ml.h (119–1,261)  
Piola et al., 2010[25] Open-label, randomized study of AL vs. Q in the 2nd and 3rd trimesters, with pharmacokinetic analysis of venous plasma samples (n = 97) 481 ng/ml (15–3,246)    
  1. AL artemether-lumefantrine; Q quinine;*90% range; AUC60h→∞.
\